Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection
Jean–Michel Pawlotsky(Université Paris-Est Créteil), Claudio Ávila, Shiv Kumar Sarin(Institute of Liver and Biliary Sciences), Nikolai V. Naoumov(Novartis (Switzerland)), Teerha Piratvisuth(Prince of Songkla University), Kelly A. Wong(Novartis (United States)), Robert Flisiak(Medical University of Białystok), Cheng‐Yuan Peng(China Medical University), Graham R. Foster(Queen Mary University of London), Heiner Wedemeyer(Medizinische Hochschule Hannover), J. Rasenack(University of Freiburg), Christophe Hézode(Inserm), Bin Li(Sun Yat-sen University), Wei Zhang(Qingdao University), Wan‐Long Chuang(Kaohsiung Medical University), Samir Shah(Global Hospitals)
Cited by 51
Related Papers
Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
|Hepatology International|2017|2.2k
Consensus Proposals for a Unified System of Nomenclature of Hepatitis C Virus Genotypes *
|Hepatology|2005|1.5k
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
|New England Journal of Medicine|2014|877